| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... The lancet Gastroenterology & hepatology 4 (5), 341-353, 2019 | 560 | 2019 |
| Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD NA Kennedy, S Lin, JR Goodhand, N Chanchlani, B Hamilton, ... Gut 70 (10), 1884-1893, 2021 | 280* | 2021 |
| Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, ... Gut 70 (5), 865-875, 2021 | 174 | 2021 |
| Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ... Nature communications 13 (1), 1379, 2022 | 71 | 2022 |
| Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients N Chanchlani, S Lin, D Chee, B Hamilton, R Nice, Z Arkir, C Bewshea, ... Journal of Crohn's and Colitis 16 (3), 389-397, 2022 | 48 | 2022 |
| Long-term outcomes in patients diagnosed with bile-acid diarrhoea S Lin, DS Sanders, JT Gleeson, C Osborne, L Messham, M Kurien European Journal of Gastroenterology & Hepatology 28 (2), 240-245, 2016 | 35 | 2016 |
| Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic NA Kennedy, M Janjua, N Chanchlani, S Lin, C Bewshea, R Nice, ... Gut 72 (2), 295-305, 2023 | 33 | 2023 |
| Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic S Lin, LHS Lau, N Chanchlani, NA Kennedy, SC Ng Gut 71 (7), 1426-1439, 2022 | 27 | 2022 |
| Quality improvement project identifies factors associated with delay in IBD diagnosis GJ Walker, S Lin, N Chanchlani, A Thomas, P Hendy, N Heerasing, ... Alimentary Pharmacology & Therapeutics 52 (3), 471-480, 2020 | 25 | 2020 |
| Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA. 1 and BA. 4/5 variants in patients with inflammatory bowel disease treated with infliximab and … Z Liu, K Le, X Zhou, JL Alexander, S Lin, C Bewshea, N Chanchlani, ... The Lancet Gastroenterology & Hepatology 8 (2), 145-156, 2023 | 24 | 2023 |
| The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients JL Alexander, BH Mullish, NP Danckert, Z Liu, ML Olbei, A Saifuddin, ... EBioMedicine 88, 2023 | 23 | 2023 |
| Root‐cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease C Gordon, D Chee, B Hamilton, NM Heerasing, P Hendy, N Chanchlani, ... Alimentary pharmacology & therapeutics 53 (2), 291-301, 2021 | 20 | 2021 |
| UK Inflammatory Bowel Disease Pharmacogenetics Study Group Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a … NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... Lancet Gastroenterol Hepatol 4 (5), 341, 2019 | 18 | 2019 |
| Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients S Lin, NA Kennedy, A Saifuddin, DM Sandoval, C Reynolds, RC Seoane, ... | 15 | 2021 |
| Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease D Chee, R Nice, B Hamilton, E Jones, S Hawkins, C Redstone, V Cairnes, ... Journal of Crohn's and Colitis 16 (2), 190-198, 2022 | 13 | 2022 |
| Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF … N Chanchlani, S Lin, MK Auth, CL Lee, H Robbins, S Looi, SV Murugesan, ... Alimentary Pharmacology & Therapeutics 56 (8), 1250-1263, 2022 | 10 | 2022 |
| Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study GJ Walker, N Chanchlani, A Thomas, S Lin, L Moore, NM Heerasing, ... Archives of Disease in Childhood 105 (10), 957-963, 2020 | 10 | 2020 |
| Clinical features and genetic risk of demyelination following anti-TNF treatment S Lin, HD Green, P Hendy, NM Heerasing, N Chanchlani, B Hamilton, ... Journal of Crohn's and Colitis 14 (12), 1653-1661, 2020 | 9 | 2020 |
| Understanding anti‐TNF treatment failure: does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients … S Lin, N Chanchlani, I Carbery, M Janjua, R Nice, TJ McDonald, ... Alimentary Pharmacology & Therapeutics 56 (5), 783-793, 2022 | 7 | 2022 |
| Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients With Active Luminal Crohn’s Disease N Chanchlani, S Lin, R Smith, C Roberts, R Nice, TJ McDonald, ... Crohn's & Colitis 360 5 (3), otad026, 2023 | 6 | 2023 |
